Trial Profile
Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 13 Sep 2022 According to ClinicalTrials.gov record, time frame for primary end point has been changed from 7years to 5years.
- 21 May 2021 Status changed from active, no longer recruiting to discontinued (Due to slow accrual)
- 08 May 2019 Planned number of patients changed to 30.